Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-DIM5 is a synthetic small molecule belonging to the family of para-phenyl–substituted diindolylmethanes. It acts as an agonist for the orphan nuclear receptor Nur77 and also recruits Nurr1 in neural cells. The neuroprotective and anti-inflammatory efficacy is mediated through upregulation of Nur77 mRNA, suppression of neuroinflammatory genes, and inhibition of NF-κB–dependent expression of inflammatory and apoptotic targets. C-DIM5 prevents nuclear export of Nur77 and recruits Nurr1 to the nucleus, leading to transrepressive effects on inflammatory signaling. It has demonstrated efficacy in preventing loss of dopaminergic neurons in mouse models of Parkinson’s disease and can induce apoptosis in colon cancer cells. Administration is typically oral, and its pharmacokinetic profile has been studied in murine models[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C-DIM5.